Clinical Research Directory

Inclusion Criteria: * Voluntary participation and written informed consent. * ≥18 years; * Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. * Confirmed platinum-resistant relapse. * According to RECIST 1.1 criteria, there must be at least one measurable lesion in the baseline. * Expected survival of more than 3 months. * ECOG performance status score of 0 or 1. * Adequate organ function. * Capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other related study procedures. Exclusion Criteria: * Primary platinum-refractory disease. * Active central nervous system metastases. * Uncontrolled pleural effusion. * Previous treatment with topoisomerase I inhibitor ADCs. * Other malignant tumors within 5 years. * Interstitial pneumonia/lung disease requiring systemic corticosteroids or suspected interstitial pneumonia/lung disease. * Uncontrolled comorbidities. * Toxicity from previous anti-cancer treatments not recovered to CTCAE Grade ≤1. * History of allogeneic bone marrow or organ transplantation. * Allergic reactions or hypersensitivity to antibody drugs. * Conditions affecting study drug treatment safety or compliance, including psychiatric disorders, alcohol abuse, or drug abuse.